JP2016513105A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513105A5
JP2016513105A5 JP2015557534A JP2015557534A JP2016513105A5 JP 2016513105 A5 JP2016513105 A5 JP 2016513105A5 JP 2015557534 A JP2015557534 A JP 2015557534A JP 2015557534 A JP2015557534 A JP 2015557534A JP 2016513105 A5 JP2016513105 A5 JP 2016513105A5
Authority
JP
Japan
Prior art keywords
galactose
glycosylated
population
seq
glycosylated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015557534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513105A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/000867 external-priority patent/WO2014125382A2/en
Publication of JP2016513105A publication Critical patent/JP2016513105A/ja
Publication of JP2016513105A5 publication Critical patent/JP2016513105A5/ja
Pending legal-status Critical Current

Links

JP2015557534A 2013-02-13 2014-02-13 改変グリコシル化を有するセツキシマブおよびその使用 Pending JP2016513105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764446P 2013-02-13 2013-02-13
US61/764,446 2013-02-13
PCT/IB2014/000867 WO2014125382A2 (en) 2013-02-13 2014-02-13 Cetuximab with modified glycosylation and uses thereof

Publications (2)

Publication Number Publication Date
JP2016513105A JP2016513105A (ja) 2016-05-12
JP2016513105A5 true JP2016513105A5 (enExample) 2017-03-09

Family

ID=50980328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557534A Pending JP2016513105A (ja) 2013-02-13 2014-02-13 改変グリコシル化を有するセツキシマブおよびその使用

Country Status (13)

Country Link
US (1) US20160002330A1 (enExample)
EP (1) EP2956484B1 (enExample)
JP (1) JP2016513105A (enExample)
KR (1) KR20150145225A (enExample)
CN (1) CN105358577A (enExample)
AR (1) AR094779A1 (enExample)
AU (1) AU2014217569B2 (enExample)
BR (1) BR112015019339A2 (enExample)
CA (1) CA2900915A1 (enExample)
IL (1) IL240442A0 (enExample)
MX (1) MX2015010429A (enExample)
TW (1) TW201444871A (enExample)
WO (1) WO2014125382A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501365A1 (en) 2010-12-30 2013-09-16 Laboratoire Francais Du Fractionnment Et Des Biotechnologies Glycols as pathogen inactivating agents
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
JP2016532100A (ja) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーLaboratoire Francais Du Fractionnement Et Des Biotechnologies アフィニティークロマトグラフィーマトリックス
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3974524A1 (en) 2015-10-08 2022-03-30 Dna Twopointo Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
WO2017120613A1 (en) * 2016-01-10 2017-07-13 Sorrento Therapeutics, Inc. Improved safety for treating cancers with a glycosylated chimeric antibody to egfr
US11649291B2 (en) * 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
KR102376545B1 (ko) * 2017-08-01 2022-03-21 삼성디스플레이 주식회사 플렉시블 디스플레이 윈도우
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2022148549A1 (en) 2020-01-14 2022-07-14 Babylat Gmbh Apparatus and method for obtaining protein-enriched fractions from breast milk

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
ATE464389T1 (de) * 2002-05-17 2010-04-15 Kyowa Hakko Kirin Co Ltd Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
CA2506629A1 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
CA2450289A1 (en) * 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
NZ568433A (en) 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
FR2901707B1 (fr) * 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
HRP20150307T1 (hr) * 2006-09-10 2015-04-24 Glycotope Gmbh Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela
WO2008101177A2 (en) * 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
EP2389586B2 (en) * 2009-01-22 2018-01-24 Momenta Pharmaceuticals, Inc. Galactose-alpha-1,3-galactose-containing n-glycans in glycoprotein products derived from cho cells
KR20120101059A (ko) * 2009-11-11 2012-09-12 모멘타 파머슈티컬스 인코포레이티드 중국 햄스터 유래의 글리코실 전이효소 및 관련 방법

Similar Documents

Publication Publication Date Title
JP2016513105A5 (enExample)
JP2016508515A5 (enExample)
JP2016509019A5 (enExample)
JP2012116856A5 (enExample)
JP2018504105A5 (enExample)
JP2012143232A5 (enExample)
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
CN103562403A8 (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
WO2018023025A8 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
PH12019502730A1 (en) Method of manufacturing bispecific antibodies and therapeutic use of such antibodies
JP2013538057A5 (enExample)
JP2011182801A5 (enExample)
JP2020504101A5 (enExample)
HRP20241498T1 (hr) Antitijela usmjerena protiv t-staničnog imunoglobulina i mucin proteina 3 (tim-3)
JP2017052784A5 (enExample)
JP2014526898A5 (enExample)
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
WO2015127136A3 (en) Ebola monoclonal antibodies
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
JP2015028021A5 (enExample)
WO2015049517A3 (en) Animal models and therapeutic molecules
JP2012121878A5 (enExample)
FI3736291T3 (fi) Anti-fcrh5-vasta-aineita
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.